. Author manuscript; available in PMC: 2010 Jun 1.

Published in final edited form as: J Allergy Clin Immunol. 2009 Jun;123(6):1328–34.e1. doi: 10.1016/j.jaci.2009.04.005

Table 6.

BMI category and change in outcomes in inhaled glucocorticoid treated subjects.

Variable	BMI < 25	BMI ≥ 25	p for difference
FEV₁ (L) (n=183/200)	0.1 [0.05, 0.16]	0.1 [0.05, 0.15]	0.8/1.0
FEV₁ (% predicted) (n=183/200)	2.50 [1.15, 3.85]	2.94 [1.65, 4.22]	0.8/0.6
FEV₁/FVC (n=119/141)	1.68 [0.81, 2.56]	1.11 [0.28, 1.93]	0.2/0.3
Morning peak expiratory flow (n=192/206)	3.21 [−1.58, 7.99]	2.48 [−2.11, 7.06]	0.5/0.8
Quality of Life (n=73/85)	0.31 [0.15, 0.48]	0.24 [0.08, 0.40]	0.4/0.5
PC₂₀ FEV₁ (n=54/68)	0.19 [−1.01, 1.39]	0.36 [−0.72, 1.44]	0.7/0.8
FeNO (n=56/64)	−6.54 [−8.88, −4.20]	−3.57 [−5.77, −1.38]	0.04/0.06
Average Daily Symptoms (n=192/206)	−0.03 [−0.05, 0.00]	−0.04 [−0.06, −0.02]	0.6/0.5
Average Daily Rescue Use (n=191/206)	−0.24 [−0.33, −0.15]	−0.20 [−0.29, −0.12]	0.4/0.5

Data presented as mean change and [95% CI]. Reported p values adjusted for baseline and baseline + study, with 1 p value reported if both identical.